Clinical Trial Update: SGS742 in Patients With Mild to Moderate Alzheimer's Disease (AD) [Phase 2]

View source ↗

Summary

A Phase 2 trial of SGS742 for Alzheimer's disease has completed, according to the sponsor Saegis Pharmaceuticals.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• SGS742

Snippet

Sponsor: Saegis Pharmaceuticals | Conditions: Alzheimer's Disease | Phase 2 | Status: COMPLETED